Author: admin

• Silver Tiger Metals Inc. recently completed a follow-on equity offering of C$40.00 million, issuing 54,800,000 common shares at C$0.73 each under Regulation S and Rule 144A, alongside reporting a smaller quarterly net loss of C$0.92 million.

• This capital raise, combined with slightly lower losses per share and increased visibility through mining investment conferences, meaningfully reshapes how investors may view the company’s funding position and project ambitions.

• We’ll now explore how the sizeable C$40.00 million equity raise influences Silver Tiger Metals’ investment narrative and future project optionality.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

To own Silver Tiger Metals, you need to believe that the El Tigre Stockwork silver-gold project can transition from permits and studies into a viable mine, while the company manages dilution and execution risk. The recent C$40.00 million equity raise, on top of earlier offerings, materially reinforces the funding side of that story and may ease near term concerns about how to advance construction after securing Mexican environmental approvals. At the same time, it amplifies the central trade off for shareholders: the company has more capital to push El Tigre forward, but existing investors now share that upside across a much larger share base. Near term catalysts still hinge on project financing milestones, construction decisions and any updates on economics, while key risks remain cost inflation, permitting or build delays and continued reliance on equity markets if spending runs ahead of plan.

However, this extra capital also sharpens a dilution risk that investors should not ignore. Despite retreating, Silver Tiger Metals’ shares might still be trading above their fair value and there could be some more downside. Discover how much.

Seven Simply Wall St Community fair value views span roughly C$3.30 to a very large C$33.00, underlining how far opinions diverge on Silver Tiger’s upside. Set that against the recent heavy equity issuance and project execution risk, and it becomes clear why you may want to weigh several viewpoints before forming your own stance on the shares.

Explore 7 other fair value estimates on Silver Tiger Metals – why the stock might be a potential multi-bagger!

Disagree with this assessment? Create your own narrative in under 3 minutes – extraordinary investment returns rarely come from following the herd.

Our top stock finds are flying under the radar-for now. Get in early:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SLVR.V.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

At the American Society of Hematology (ASH) 2025 meeting, updated results from the phase 2 EPCORE NHL‑2 (NCT04663347) trial highlighted the potential of epcoritamab combined with chemotherapy to improve outcomes for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), spanning both high-risk and frail or older populations.

The EPCORE NHL‑2 trial phase 1b/2 enrolled adults with newly diagnosed CD20-positive DLBCL who were ineligible for full-dose R‑CHOP due to age (75 years and older) or age 65 years and older with significant comorbidities.¹ Patients received a fixed-duration regimen of subcutaneous epcoritamab 48 mg combined with R‑mini‑CHOP. Epcoritamab was administered weekly in cycles 1–2, every 3 weeks in cycles 3–6, and every 4 weeks in cycles 7–8, with step-up dosing during the cycle. The primary end point was overall response rate (ORR). Secondary end points included minimal residual disease (MRD) negativity, assessed using the AVENIO Oncology circulating tumor DNA (ctDNA) assay, with MRD negativity defined as less than 1 mutant molecule/mL. Safety, treatment completion, and relative dose intensity of R‑mini‑CHOP were also evaluated.

As of April 9, 2025, 28 patients received epcoritamab plus R-mini-CHOP. Median (IQR) age was 81 (74, 90) years. Most patients (79%) completed treatment, with a median R-mini-CHOP dose intensity of 94% or greater. ORR was 89% and the CR rate was 86%, while the median duration of response and complete response (CR) were not reached. Estimated 2-year progression-free survival (PFS) and overall survival (OS) were 76% and 82%, respectively. MRD negativity was achieved in 95% of evaluable patients, including 93% with International Prognostic Index (IPI) 3 through 5 and 89% with bulky disease; 86% of patients MRD-negative at C3D1 sustained negativity through C6D1. Grade 3 or greater infections occurred in 29% of patients, and 11% discontinued epcoritamab due to treatment-emergent adverse events.

In the second analysis, patients received fixed-duration epcoritamab in combination with 6 cycles of standard R‑CHOP, followed by epcoritamab monotherapy for up to 1 year.² Epcoritamab was administered subcutaneously with step-up dosing during cycle 1 and weekly in cycles 1–4, then every 3 weeks in cycles 5–6, with subsequent monthly monotherapy. The study evaluated efficacy using investigator-assessed ORR as the primary end point. Secondary end points included CR rate, duration of response, PFS and OS, safety, and tolerability. MRD negativity was also assessed.

A total of 47 patients received epcoritamab plus R‑CHOP. Median age was 64 (19, 82) years. IPI scores were 3 in 57% of patients and 4–5 in 38%. After a median follow-up of 38.8 (0.8, 44.3) months, ORR was 98% and CR rate was 85%, with 67% of responses and 75% of CRs ongoing at 33 months.

High CR rates were observed across subgroups (IPI 3, 86% vs IPI 4-5, 83%), age, tumor size, and cell of origin. By cycle 3 day 1, 86% of MRD-evaluable patients were MRD negative, with sustained reductions in ctDNA through cycle 6 day 1. Most patients (94%) completed 6 cycles of R‑CHOP, and 68% completed treatment as planned; among these, 30 of 32 patients had a CR, with 87% maintaining response at a median 25.3-month follow-up. Safety was consistent with prior reports, with serious or grade 3 or greater infections primarily in the first 6 months and no new grade 5 events reported.

References

1. Cheah C, Belada D, Darrah J, et al. Epcoritamab plus R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial. Presented at: ASH 2025; December 6-9, 2025; Orlando, Florida. Poster 64

2. Falchi L, de Vos S, Brody J, et al. Fixed-duration epcoritamab plus R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial. Presented at: ASH 2025; December 6-9, 2025; Orlando, Florida. Poster 1955